<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462459</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0927</org_study_id>
    <secondary_id>1R01HS025713-01</secondary_id>
    <secondary_id>A534265</secondary_id>
    <secondary_id>SMPH/MEDICINE/INFECT DIS</secondary_id>
    <secondary_id>Protocol ver 6, 18 Nov 2020</secondary_id>
    <nct_id>NCT03462459</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection</brief_title>
  <official_title>Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing&#xD;
      recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one&#xD;
      CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition.&#xD;
      Participants will be randomized to receive either placebo or oral vancomycin in addition to&#xD;
      their prescribed antibiotic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients who have a CDI experience recurrent or relapsing symptoms. The investigators&#xD;
      are studying whether vancomycin in low doses will help prevent further CDI episodes and how&#xD;
      this therapy impacts patients' gastrointestinal microbiome and composition.&#xD;
&#xD;
      Patients with a history of past CDI who are receiving antibiotics for a non-CDI condition&#xD;
      will be invited to participate. Approximately half of the participants will receive a&#xD;
      low-dose capsule of vancomycin and half will receive a placebo. Participants will continue&#xD;
      taking the vancomycin/placebo for 5 days after their prescribed antibiotics end.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Clostridium difficile infection (CDI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Determine whether CDI recurrence is decreased in patients taking oral vancomycin as prophylactic therapy in addition to standard-of-care antibiotics that patients are taking for non-CDI reasons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Study how the gut microbiome is altered in patients receiving vancomycin treatment compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo</measure>
    <time_frame>8 weeks</time_frame>
    <description>Low-dose exposure to vancomycin and VRE infection has not been studied. We will examine the incidence of VRE colonization in all patients and determine whether oral vancomycin increases the VRE colonization rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Stool samples will be tested at baseline, at the last dose date of vancomycin or placebo, at approximately 8 weeks following the last dose of vancomycin or placebo, and as indicated for diarrhea symptoms. Samples will be collected and tested for the presence of Clostridium difficile.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Recurrent Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>CDI</condition>
  <condition>C.Difficile Diarrhea</condition>
  <condition>C. Diff Colitis</condition>
  <condition>C.Difficile Colitis</condition>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin capsule, 125 mg</description>
    <arm_group_label>Vancomycin</arm_group_label>
    <other_name>Vancomycin Hydrochloride</other_name>
    <other_name>Vancocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to provide informed consent.&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Documented diagnosis of at least one CDI within the last 180 days with treatment&#xD;
             completed.&#xD;
&#xD;
          -  Currently receiving systemic antibiotics for a non-CDI condition with anticipated&#xD;
             duration of no more than 2 weeks.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test prior to&#xD;
             randomization and agree to use adequate contraception prior to randomization, for the&#xD;
             duration of the study, and for 4 weeks following study completion.&#xD;
&#xD;
          -  Have received no more than 72 hours of non-CDI antibiotics.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity or allergy to oral vancomycin.&#xD;
&#xD;
          -  Current use of oral vancomycin&#xD;
&#xD;
          -  Patients on concurrent treatment with metronidazole or tetracycline monotherapy for&#xD;
             any indication&#xD;
&#xD;
          -  Patients diagnosed with inflammatory bowel disorder (Crohn's disease), or bacterial&#xD;
             gastrointestinal infection cause by agents other than C. difficile (e.g. Salmonella&#xD;
             sp.), toxic megacolon and/or known small bowel ileus.&#xD;
&#xD;
          -  Dysphagia (inability to swallow capsules) or unwilling to swallow capsules.&#xD;
&#xD;
          -  Major gastrointestinal surgery within 3 months of enrollment (does not include&#xD;
             appendectomy or cholecystectomy).&#xD;
&#xD;
          -  Any history of total colectomy or bariatric surgery.&#xD;
&#xD;
          -  Unable or unwilling to fulfill study requirements.&#xD;
&#xD;
          -  Expected life expectancy &lt; 6 months.&#xD;
&#xD;
          -  Patients enrolled in another clinical trial with investigational drugs within 30 days&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
          -  Any patient deemed not suitable for study participation at the discretion of the study&#xD;
             investigator.&#xD;
&#xD;
          -  Diarrhea (3 or more loose stools in a 24 hour period) at enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasia Safdar, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Perzynski, BSW</last_name>
    <phone>608-265-8799</phone>
    <email>jperzynski@medicine.wisc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele L Zimbric, BS</last_name>
    <phone>608-265-8799</phone>
    <email>mzimbric@medicine.wisc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Gastroenterology &amp; Hepatology, Mayo clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hotschulte</last_name>
      <phone>507-284-9709</phone>
      <email>hofschulte.rebecca@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Sahil Khanna, MBBS, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra L Haight, BSN RN</last_name>
      <phone>608-262-6560</phone>
      <email>CDIstudy@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shelly L Zimbric, BS</last_name>
      <phone>608-265-8799</phone>
      <email>mzimbric@medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nasia Safdar, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral vancomycin</keyword>
  <keyword>vancomycin</keyword>
  <keyword>antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03462459/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03462459/ICF_004.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

